48results about How to "Improve the effect of immunotherapy" patented technology

The invention provides preparation and an application of a novel enhanced GPC3-AFP-NY-ESO-1 binding polypeptide-induced hepatoma-specific CTL cell. In the preparation and the application provided by the invention, novel hepatoma cell surface antigen polypeptides screened from GPC3, AFP and NY-ESO-1 are selected for sequential fragment ligation. The newly screened GPC3, AFP, and NY-ESO-1 polypeptides are sequentially ligated into a CTL antigen peptide as shown in SEQ ID NO. 4. In the preparation and the application provided by the invention, a novel method and means for efficient and specific tumor killing for a hepatoma cell are established, and the obtained hepatoma-specific killing CTL cell overcomes the key problems of low efficiency of tumor killing and too long culture time, and can specifically enhance the effect of hepatoma immunological therapy, thereby having an application prospect of tumor treatment.

The invention discloses a water-soluble IDO (dioxygenase) inhibitor cisplatin and a preparation method and application thereof. The water-soluble IDO inhibitor cisplatin medicine synthesized with the preparation method comprises a hydrophilic compound formed by the coordination of an IDO inhibitor, or the derivative of the IDO inhibitor and a platinum antitumor drug. Compared with other IDO inhibitors, the IDO inhibitor cisplatin prepared with the preparation method has good water solubility, and the problem of low solubility of the IDO inhibitor is solved. Meanwhile, the water-soluble IDO inhibitor cisplatin medicine keeps the activity of the IDO inhibitor, improves an immunosuppression environment, keeps the killing function of the platinum drug for tumor cells, accelerates the releasing of tumor antigens, and increases an immunotherapy effect to achieve a purpose of the collaborative treatment of tumors.

The invention discloses a cell culture method for improving DC-CIK (dendritic cell-cytokine-induced killer) cell killing ability. The cell culture method includes subjecting cultured DCs and CIKs to mixed culture in mixed culture liquid, wherein stimulating peptides shown in SEQ ID NO.1 are added into the mixed culture liquid and used for mixed culture of the DCs and the CIKs so as to stimulate to form DC-CIK cells. By changing the component of a culture system, the cell culture method changes the inhibiting effect between the DCs and the CIKs into the stimulating effect, so that the ability of the DC-CIK cells to kill target cells after co-culture can be improved, and improvement in immunological therapy effects is benefited.

The invention belongs to the technical field of medicines, particularly relates to A2A-targeting benzimidazopyrazine-3-formamide and a tumor immune function thereof, and discloses a subtype selective adenosine A2A receptor antagonist, namely a 1-amino-N-(pyridine-2-yl methyl) benzo [4, 5] imidazopyrazine-3-formamide small molecule compound, of which the structure is shown as a formula (I). Researches find that the small molecule compound can specifically target A2AR, inhibit cAMP accumulation, promote release of immune cell cytokines, enhance killing of immune cells on tumor cells in co-culture and enhance the tumor immunotherapy effect. The polypeptide shows an obvious tumor immunoenhancement effect in molecular level, cellular level and cancer mouse models, and is expected to be applied to tumor immunotherapy.

The invention provides an antagonistic peptide, a copolymer thereof, a nano-assembly as well as preparation methods and applications of the antagonistic peptide, the copolymer and the nano-assembly. The antagonistic peptide is a PD-L1 antagonistic peptide, is named M-APP, and has a structure shown in the specification. The M-APP is used as a raw material to prepare the copolymer IR780-M-APP with aclear structure, the copolymer IR780-M-APP can be self-assembled to form the nano-assembly, so that the problem of poor immunogenicity in immunotherapy is solved, and the utilization rate of the immune antagonistic peptide is improved; and through photodynamic therapy, the problem of poor water solubility of IR780 can be solved, the effect of phototherapy is improved, and the efficacy of immunotherapy is enhanced.

The invention relates to the technical field of medicine, in particular to an enzyme-sensitive nano system targeting T cells and its preparation method and application. The enzyme-sensitive nanosystem targeting T cells provided by the present invention is based on a polypeptide carrier and can be loaded with hydrophobic therapeutic drugs. The end of the polypeptide is modified with a functional group and can be connected with a functional antibody targeting T cells. The polypeptide carrier includes a hydrophobic segment and a hydrophilic segment, which can self-assemble into micelles and have good drug-loading capacity; the end of the polypeptide introduces a maleimide group, which can be connected to functional antibodies such as antibodies targeting T cell surface proteins. substance. The present invention provides a new nano system for drug delivery, which can target T cells to deliver hydrophobic therapeutic drugs and antibody drugs, restore the function of immune cells, thereby promoting the apoptosis of prostate cancer cells, and is a new method of immunotherapy for prostate cancer. An efficient and low toxicity nanoscale delivery system.

The invention discloses magnetotactic immune cells. The magnetotactic immune cells comprise immune cells and magnetic nanoparticles taken into the immune cells. The magnetotactic immune cells disclosed by the invention can be effectively enriched in a tumor site to improve targeting of the cell immunotherapy.

The invention discloses application of IFN-alpha and HDACi to preparation of a medicine for treating tumor, and belongs to the technical field of biotechnology and medical technology. Application of the IFN-alpha and HDACi disclosed by the invention to preparation of the medicine for treating tumor is disclosed. By using HDACi inhibitor, tumor cancers are treated, and then IFN-alpha is added, andverification shows that the inhibitor for epigenetic modification can further activate interferon-related signaling pathway STAT and expression of interferon responsive genes, recruits and activates parts, reaching the tumors, of immune cell subpopulations while inflammatory reaction of the inhibitor is enhanced, and the immunotherapy effect of the tumors is improved.

The invention discloses a hydrophobic-modified polyethyleneimine and application thereof as a protein carrier. The structural general formula of the hydrophobic-modified polyethyleneimine is disclosed in the specification, wherein n is any natural number ranging from 5 to 20, and X is Cl, Br or I. The hydrophobic-modified polyethyleneimine can be compounded with protein to form stable nanoparticles, and thus, can be used as a protein carrier. Compared with the prior art, the hydrophobic-modified polyethyleneimine disclosed by the invention has strong protein binding force, can carry antigen protein, can be recognized by antigen presenting cells, and can initiate immunoreaction; and meanwhile, the hydrophobic-modified polyethyleneimine enhances the antigen cross-presentation effect, obviously lowers the cytotoxicity, is beneficial to enhancing the immunotherapeutic effect, and is an excellent therapeutic tumor vaccine nano carrier system.